Invention Grant
- Patent Title: 1,4 oxazines as BACE1 and/or BACE2 inhibitors
- Patent Title (中): 1,4个恶嗪作为BACE1和/或BACE2抑制剂
-
Application No.: US13357640Application Date: 2012-01-25
-
Publication No.: US08399459B2Publication Date: 2013-03-19
- Inventor: Matteo Andreini , Emanuele Gabellieri , Robert Narquizian , Massimiliano Travagli , Wolfgang Wostl
- Applicant: Matteo Andreini , Emanuele Gabellieri , Robert Narquizian , Massimiliano Travagli , Wolfgang Wostl
- Applicant Address: US NJ Nutley IT Siena
- Assignee: Hoffmann-La Roche Inc.,Siena Biotech SpA
- Current Assignee: Hoffmann-La Roche Inc.,Siena Biotech SpA
- Current Assignee Address: US NJ Nutley IT Siena
- Agent George W. Johnston; Patricia S. Rocha-Tramaloni; Kimberly J. Prior
- Priority: EP11153095 20110202
- Main IPC: A61K31/535
- IPC: A61K31/535 ; C07D265/28
Abstract:
The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
Public/Granted literature
- US20120196863A1 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS Public/Granted day:2012-08-02
Information query
